Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
Business Wire•04/11/2026•09:01 ET
0
Key Highlights
- ➤IM-1021 produced a 53% objective response rate in 19 response-evaluable B-NHL patients
- ➤DLBCL patients recorded a 64% objective response rate, including three complete responses
- ➤35 patients received IM-1021; 25 had B-NHL as of June 26, 2026
- ➤Grade ≥3 treatment-emergent adverse events affected 52% of B-NHL patients
- ➤Neutropenia was the most common Grade ≥3 adverse event, affecting 44% of B-NHL patients
Expert Statements
Bob Lechleider, Chief Medical Officer of Immunome
“At this interim read, we were encouraged to see clinical activity with IM-1021 in these heavily pretreated patients, including patients whose disease had progressed following T-cell redirecting therapies.”
Bob Lechleider, Chief Medical Officer of Immunome
“These early results support our dose optimization efforts as we work to advance IM-1021 and further evaluate its potential for patients with B-cell lymphomas.”
Bob Lechleider, Chief Medical Officer of Immunome
“The study is ongoing, and we look forward to presenting an updated dataset at ASH.”
Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026
* Initial results demonstrate objective responses across all dose levels evaluated in heavily pretreated patients with B-cell non-Hodgkin lymphoma (B-NHL)
Get started
Create a free account to read the full story.